Home » Authors » Randy Osborne

Articles by Randy Osborne

GPC's Satraplatin NDA Done, Drug Could Launch This Year

Feb. 20, 2007

By Randy Osborne

Momenta's Momentum: FDA, Not Court, Seen As Key Now

Feb. 19, 2007

By Randy Osborne

Record Genzyme Revenues Clipped By AnorMED Buyout

Feb. 15, 2007

By Randy Osborne

Locus Round Raises $30.2M To Push Cancer Drug, More

Feb. 14, 2007

By Randy Osborne

Gilead, Achillion HCV Push Hits Bump, Changes Focus

Feb. 12, 2007

By Randy Osborne

Moving Beyond The Niche: BioMarin's News Due Soon

Feb. 12, 2007

By Randy Osborne

Corautus Ending Suspense, Discloses Merger With VIA

Feb. 9, 2007

By Randy Osborne

Wyeth's Pair Of Hemophilia Deals Target Longer Action

Feb. 6, 2007

By Randy Osborne

Schering-Plough Pays Up To $625M For Anacor Antifungal

Feb. 5, 2007

By Randy Osborne

NTI: Snakes Could Increase Stroke Treatment Window

Feb. 5, 2007

By Randy Osborne

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Wuxi Apptec insists it’s ‘not a Chinese military company’
BioWorld
Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.